{"schema_version":"secwatch.filing_event.v1","accession":"0001434647-25-000009","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.402913+00:00","generated_at":"2026-05-17T00:14:19.787865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zevra Q3 net loss narrows to $0.5M; revenue jumps to $26.1M on MIPLYFFA sales","bullets":["Q3 net revenue $26.1M (vs $3.7M YoY), with MIPLYFFA contributing $22.4M.","Net loss $(0.5)M or $(0.01) per share vs $(33.2)M or $(0.69) per share in Q3 2024.","MIPLYFFA prescription enrollment forms total 137 since launch; market access 66% of covered lives.","Cash and securities $230.4M as of Sep 30, 2025; company believes sufficient to fund operations.","Arimoclomol EMA application validated under review; celiprolol Phase 3 trial enrolled 44 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001434647-25-000009","json":"https://secwatch.observer/filing/0001434647-25-000009.json","markdown":"https://secwatch.observer/filing/0001434647-25-000009.md","text":"https://secwatch.observer/filing/0001434647-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143464725000009/0001434647-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143464725000009/zvra-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:14:19.787865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}